These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
74 related items for PubMed ID: 26916450
1. Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations. Orozco-Beltran D, Pan C, Svendsen AL, Faerch L, Caputo S, SOLVE Study Group. Int J Clin Pract; 2016 Mar; 70(3):236-43. PubMed ID: 26916450 [Abstract] [Full Text] [Related]
6. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604 [Abstract] [Full Text] [Related]
7. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Marre M, Pinget M, Gin H, Thivolet C, Hanaire H, Robert JJ, Fontaine P. Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118 [Abstract] [Full Text] [Related]
12. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification. Malek R, Ajili F, Assaad-Khalil SH, Shinde A, Chen JW, Van den Berg E. Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023 [Abstract] [Full Text] [Related]
13. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice. Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL, SOLVE Study Group. J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141 [Abstract] [Full Text] [Related]
14. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Davies M, Evans R, Storms F, Gomis R, Khunti K. Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063 [Abstract] [Full Text] [Related]
15. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel. Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170 [Abstract] [Full Text] [Related]
16. Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. Kalirai S, Stephenson J, Perez-Nieves M, Grabner M, Hadjiyianni I, Geremakis C, Pollom RD, Reed B, Fisher L. Prim Care Diabetes; 2018 Apr; 12(2):155-162. PubMed ID: 29100717 [Abstract] [Full Text] [Related]
20. Changes in health services usage associated with insulin initiation in primary care. Johnson S, Thuraisingam S, Furler J, Nankervis JM. Aust J Prim Health; 2018 May; 24(2):155-161. PubMed ID: 29544598 [Abstract] [Full Text] [Related] Page: [Next] [New Search]